文献速递消化道肿瘤放疗姑息放疗与转移瘤

降阶梯全程新辅助治疗用于直肠癌非手术治疗:NOM-3/TNT前瞻性队列研究结果

De-escalated total neoadjuvant therapy for the non-operative management of rectal cancer: Results of the NOM-3/TNT prospective cohort study.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-08-20

结果显示66%患者进入观察等待,但再生长率达44%,2年持续临床完全缓解(cCR)率为36%,器官保留适配无病生存率为66%。

要点

  • 化疗中点评估可识别反应不佳者并提前终止化疗,6周组3-4级急性毒性为17%,12周组为33%。
  • 66%患者进入观察等待(8例cCR,8例near-cCR),33%反应不佳者直接行全直肠系膜切除术(TME)。
  • 再生长发生于44%观察等待患者,cCR组再生长率13%,near-cCR组为75%。

核心结论

  • 四分类肿瘤反应评估(化疗中点反应不佳、持续肿瘤、near-cCR和cCR)可能降低选定患者的毒性。

研究设计与样本

  • 患者接受短程放疗后12周FOLFOX4巩固化疗,化疗中点(6周)行初始肿瘤反应评估。

主要发现

  • 6例(25%)患者基于初始评估终止化疗,其中1例达cCR,5例反应不佳。
  • 6周化疗组3-4级急性毒性为17%,12周化疗组为33%。
  • 16例(66%)患者进入观察等待(8例cCR,8例near-cCR),8例(33%)行TME。
  • 观察等待患者中7例(44%)出现再生长,cCR组1/8(13%),near-cCR组6/8(75%)。
  • 5例再生长患者行挽救性TME,2例拒绝TME;中位随访20个月,2年持续cCR率为36%(95%CI 16-56),器官保留适配无病生存率为66%(95%CI 45-87)。

临床怎么用

  • 对小型和中型低位直肠癌可考虑降阶梯TNT联合化疗中点反应评估,以筛选观察等待候选者并减少毒性。
  • near-cCR患者再生长风险较高,需加强随访监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Total neoadjuvant therapy (TNT) enables non-operative management, although at the cost of increased toxicity. We evaluated a de-escalated TNT-based watch-and-wait (w-w) regimen aimed at reducing toxicity and improving oncological safety through early surgery for poor-responding tumours. MATERIAL AND METHODS: Patients with small and intermediate-sized low-lying tumours (cT2-3/T4b N0-2) received short-course radiotherapy followed by 12 weeks of consolidation FOLFOX4. Initial tumour response assessment was performed at the midpoint of chemotherapy (six weeks). RESULTS: Twenty-four patients were included. Based on the initial tumour response assessment, chemotherapy was discontinued in six (25%) patients, including one witha clinical complete response (cCR) and five with a poor response. Grade 3-4 acute toxicity was 17% in the 6-week chemotherapy group and 33% in the 12-week chemotherapy group. Following the initial and second (final) assessments, 16 (66%) patients initiated w-w (eight with cCR and eight with near-cCR), while eight (33%) with a poor-responding/persistent tumour proceeded to total mesorectal excision (TME). Regrowth occurred in seven (44%) patients, including one (13%) of eight who achieved cCR and six (75%) of eight who achieved near-cCR. Five patients with regrowth proceeded to salvage TME, whereas the remaining two refused TME. With a median follow-up of 20 months, sustained cCR at 2 years was 36% (95% confidence interval [CI]: 16-56) and organ preservation adapted disease-free survival 66% (95% CI: 45-87). CONCLUSION: Our results suggest that the four-tier classification of tumour response (poor response at the midpoint of chemotherapy, persistent tumour, near-cCR and cCR) may reduce toxicity in selected patients.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Skrzypiec B, Paciorek K, Pietrzak L, et al. De-escalated total neoadjuvant therapy for the non-operative management of rectal cancer: Results of the NOM-3/TNT prospective cohort study. Clin Transl Radiat Oncol. 2026. PMID: 42703503. doi:10.1016/j.ctro.2026.101266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。